The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients

Zhang Wei Xia,Chen Yong Jun,Chen Hao,Chen Bing,Shi Min Min,Xie Jun Jie

DOI: https://doi.org/10.1007/s00228-010-0833-2

2010-01-01

European Journal of Clinical Pharmacology

Abstract:Purpose Mycophenolate mofetil (MMF) is a pro-drug that is hydrolyzed to release mycophenolic acid (MPA). Subsequently MPA is extensively metabolized to phenyl mycophenolic acid glucuronide (MPAG) and MPA acyl glucuronide (AcMPAG). It was presumed that the closest association is between plasma AcMPAG concentrations and the incidence of diarrhea. This study aimed to investigate the correlation between pharmacokinetics of MPA, MPAG, and AcMPAG and diarrhea in liver transplant recipients on MMF with tacrolimus. Methods Sixty-seven patients receiving liver transplantation were included. The pharmacokinetics of MPA and its metabolites were monitored repeatedly in the early stage (within 2 weeks) and in the late stage after transplant. The plasma concentrations of MPA, MPAG, and AcMPAG were determined by the HPLC method. Results Twenty-two patients (32.8%) suffered from episodes of diarrhea. Compared with the data from the early stage, AUC 0–12h of MPA, MPAG, and AcMPAG increased significantly in both groups in the later stage. AUC 0-12h of MPA, MPAG, and AcMPAG were not different significantly between the group with diarrhea and the group without diarrhea, either in the early stage or in the late stage ( P > 0.05). Conclusion These results suggest that systemic exposures to MPA and its metabolites are not associated with the incidence of diarrhea in liver transplant recipients.